Literature DB >> 7328059

Inhibition of lymph node metastasis of P388 leukemia by bestatin in mice.

T Tsuruo, K Naganuma, H Iida, T Yamori, S Tsukagoshi, Y Sakurai.   

Abstract

Bestatin, a chemically defined immunostimulant of low molecular weight, suppressed the gradually-occurring lymph node metastasis of P388 leukemia in CDF1 mice when administered i.p. at the doses of 1 approximately 30 micrograms/mouse. It could not, however, suppress the established large metastasis of P388 leukemia. Lymph node cells isolated from the mice given bestatin i.p. at 1 and 30 microgram/mouse showed cytostatic activity against P388 leukemic cells in vitro than those from the untreated mice.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7328059     DOI: 10.7164/antibiotics.34.1206

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  7 in total

1.  Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases.

Authors:  F Abe; G Alvord; M Koyama; A Matsuda; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.

Authors:  Yunching Chen; Surendar Reddy Bathula; Jun Li; Leaf Huang
Journal:  J Biol Chem       Date:  2010-05-11       Impact factor: 5.157

3.  Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13.

Authors:  H Fujii; M Nakajima; I Saiki; J Yoneda; I Azuma; T Tsuruo
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

4.  Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice.

Authors:  F Abe; A Matsuda; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice.

Authors:  F Abe; M Schneider; P L Black; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 6.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

7.  Inhibition of aminopeptidases N, A and W. A re-evaluation of the actions of bestatin and inhibitors of angiotensin converting enzyme.

Authors:  S Tieku; N M Hooper
Journal:  Biochem Pharmacol       Date:  1992-11-03       Impact factor: 5.858

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.